Trial Profile
A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Alogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Takeda
- 20 Dec 2016 Results assessing pharmacokinetics and pharmacodynamics published in the European Journal of Clinical Pharmacology.
- 27 Dec 2013 Status changed from recruiting to completed , as per ClinicalTrials.gov record.
- 26 Nov 2012 Planned end date changed from 1 Nov 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov record.